» Articles » PMID: 37393702

Predictors of Seizure Outcomes of Autoimmune Encephalitis: A Clinical and Morphometric Quantitative Analysis Study

Overview
Publisher Elsevier
Specialty Neurology
Date 2023 Jul 2
PMID 37393702
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Autoimmune encephalitis can be followed by treatment-resistant epilepsy. Understanding its predictors and mechanisms are crucial to future studies to improve autoimmune encephalitis outcomes. Our objective was to determine the clinical and imaging predictors of postencephalitic treatment-resistant epilepsy.

Methods: We performed a retrospective cohort study (2012-2017) of adults with autoimmune encephalitis, both antibody positive and seronegative but clinically definite or probable. We examined clinical and imaging (as defined by morphometric analysis) predictors of seizure freedom at long term follow-up.

Results: Of 37 subjects with adequate follow-up data (mean 4.3 yrs, SD 2.5), 21 (57 %) achieved seizure freedom after a mean time of 1 year (SD 2.3), and one third (13/37, 35 %) discontinued ASMs. Presence of mesial temporal hyperintensities on the initial MRI was the only independent predictor of ongoing seizures at last follow-up (OR 27.3, 95 %CI 2.48-299.5). Morphometric analysis of follow-up MRI scans (n = 20) did not reveal any statistically significant differences in hippocampal, opercular, and total brain volumes between patients with postencephalitic treatment-resistant epilepsy and those without.

Significance: Postencephalitic treatment-resistant epilepsy is a common complication of autoimmune encephalitis and is more likely to occur in those with mesial temporal hyperintensities on acute MRI. Volume loss in the hippocampal, opercular, and overall brain on follow-up MRI does not predict postencephalitic treatment-resistant epilepsy, so additional factors beyond structural changes may account for its development.

Citing Articles

Prognostic factors underlying the development of drug-resistant epilepsy in patients with autoimmune encephalitis: a retrospective cohort study.

Huang W, Zhang H, Li X, Zhang J, Chen J, Chen Z J Neurol. 2024; 271(8):5046-5054.

PMID: 38801431 DOI: 10.1007/s00415-024-12432-y.

References
1.
Destrieux C, Fischl B, Dale A, Halgren E . Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage. 2010; 53(1):1-15. PMC: 2937159. DOI: 10.1016/j.neuroimage.2010.06.010. View

2.
de Bruijn M, van Sonderen A, van Coevorden-Hameete M, Bastiaansen A, Schreurs M, Rouhl R . Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABAR encephalitis. Neurology. 2019; 92(19):e2185-e2196. PMC: 6537134. DOI: 10.1212/WNL.0000000000007475. View

3.
Steriade C, Jehi L, Krishnan B, Morita-Sherman M, Moosa A, Hantus S . Perisylvian vulnerability to postencephalitic epilepsy. Clin Neurophysiol. 2020; 131(8):1702-1710. PMC: 7879563. DOI: 10.1016/j.clinph.2020.04.019. View

4.
Steriade C, Britton J, Dale R, Gadoth A, Irani S, Linnoila J . Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia. 2020; 61(7):1341-1351. DOI: 10.1111/epi.16571. View

5.
Zhang X, Lang Y, Sun L, Zhang W, Lin W, Cui L . Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China. BMC Neurol. 2020; 20(1):1. PMC: 6941279. DOI: 10.1186/s12883-019-1585-y. View